MPR4d
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
In a recent study, significantly more patients receiving the combination therapy met primary end point of reduction in spleen volume.
News Medical on MSN4d
Open-access machine learning model enhances transplant risk assessment in myelofibrosis patients
A machine learning model generated by a team from the European Society for Blood and Marrow Transplantation (EBMT) ...
Healio15d
VIDEO: Novel therapies showing promise in myelofibrosis
In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.
American Association of Individual Investors4d
Which Is a Better Investment, Alvotech or Grifols, S.A. Stock?
Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...
Dr Boreham’s Crucible: This rare blood disease tackler aims to hit investors with its best shot
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...
Medscape26d
What's Next? Clinical Trials in Myelofibrosis
The spleen and symptoms endpoints evolved as a ... improvement in the JAK2 variant allele percentage, and improvements in fibrosis. These endpoints, I think, are interesting, but I still view ...
Medical Xpress5d
Open-access machine learning model enhances transplant risk assessment in myelofibrosis patients
This leads to the formation of scar tissue within the bones, resulting in anemia and migration of stem cells to other organs, primarily the spleen and ... of bone marrow fibrosis and the presence ...